Literature DB >> 15885939

Impurity formation studies with peptide-loaded polymeric microspheres Part II. In vitro evaluation.

Santos B Murty1, Dong Hee Na, B C Thanoo, Patrick P DeLuca.   

Abstract

Since acylated peptide impurities were isolated from octreotide microspheres following incubation in an in vivo environment, the present investigation was undertaken to determine the dosage form dynamics responsible for facilitating acylation. In particular, microsphere batches made with poly(L-lactide) (PLA) and poly(lactide-co-glycolide) (PLGA) 85:15 were studied for in vitro drug release, mass balance relationships, mass loss behavior, hydration uptake, and solid-state stability. Furthermore, native octreotide was incubated in a varying pH stability model (heat treated lactic acid solutions 42.5%, w/w) to determine the effects of acidity on impurity formation. From a review of the experimental results, the appearance of octreotide impurities or related substances occurred with the onset of polymeric mass loss. In fact, the significant formation of acylated peptide did not appear until >90% mass loss, which was observed at 14 days. It was surmised that because of water uptake, the hydrolytic cleavage of the polymeric backbone created an acidic microenvironment to facilitate the covalent coupling of peptide with polymer. The lactic acid solution stability model corroborated with greater evidence of acylation at pH 2.25 where the presence lactoyl (+72 m/z) derivatives of octreotide were confirmed by MALDI-TOF mass spectrometry.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885939     DOI: 10.1016/j.ijpharm.2005.02.034

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

1.  Reversible blocking of amino groups of octreotide for the inhibition of formation of acylated peptide impurities in poly(lactide-co-glycolide) delivery systems.

Authors:  Jae Hwa Ahn; Eun Ji Park; Hye Suk Lee; Kang Choon Lee; Dong Hee Na
Journal:  AAPS PharmSciTech       Date:  2011-09-21       Impact factor: 3.246

2.  Effect of excipients on PLGA film degradation and the stability of an incorporated peptide.

Authors:  M L Houchin; S A Neuenswander; E M Topp
Journal:  J Control Release       Date:  2006-12-01       Impact factor: 9.776

3.  Acylation of exenatide by glycolic acid and its anti-diabetic activities in db/db mice.

Authors:  Rongcai Liang; Xiang Li; Renyu Zhang; Yanan Shi; Aiping Wang; Daquan Chen; Kaoxiang Sun; Wanhui Liu; Youxin Li
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

4.  A new class of inhibitors of peptide sorption and acylation in PLGA.

Authors:  Andreas M Sophocleous; Ying Zhang; Steven P Schwendeman
Journal:  J Control Release       Date:  2009-03-24       Impact factor: 9.776

5.  Formation of acylated growth hormone-releasing peptide-6 by poly(lactide-co-glycolide) and its biological activity.

Authors:  Dong Hee Na; Jeong Eun Lee; Sun Woo Jang; Kang Choon Lee
Journal:  AAPS PharmSciTech       Date:  2007-06-08       Impact factor: 3.246

6.  The solution and solid state stability and excipient compatibility of parthenolide in feverfew.

Authors:  Ping Jin; Shadi Madieh; Larry L Augsburger
Journal:  AAPS PharmSciTech       Date:  2007-12-14       Impact factor: 3.246

7.  Controlled release of octreotide and assessment of peptide acylation from poly(D,L-lactide-co-hydroxymethyl glycolide) compared to PLGA microspheres.

Authors:  Amir H Ghassemi; Mies J van Steenbergen; Arjan Barendregt; Herre Talsma; Robbert J Kok; Cornelus F van Nostrum; Daan J A Crommelin; Wim E Hennink
Journal:  Pharm Res       Date:  2011-07-09       Impact factor: 4.200

8.  Identification and Assessment of Octreotide Acylation in Polyester Microspheres by LC-MS/MS.

Authors:  Mehrnoosh Shirangi; Wim E Hennink; Govert W Somsen; Cornelus F van Nostrum
Journal:  Pharm Res       Date:  2015-04-02       Impact factor: 4.200

9.  PEGylation of Octreotide Using an α,β-unsaturated-β'-mono-sulfone Functionalized PEG Reagent.

Authors:  Laleh Erfani-Jabarian; Rasoul Dinarvand; Mohammad Reza Rouini; Fatemeh Atyabi; Mohsen Amini; Negar Mohammadhosseini; Abbas Shafiee; Alireza Foroumadi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.